Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company. The DAYBREAK results reinforce Zenkuda's potential to become a first-line therapy in wet AMD, combining rapid disease control with a 24-week dosing interval for the majority of patients under strict treat-to-dry and maintain dry criteria reflective of real-world clinical practice. Tabirafusp-ted has delivered a positive Phase 3 readout in wet AMD and is actively enrolling in our Phase 3 ALTO study in diabetic macular edema. And KSI-101 is rapidly approaching its first pivotal readout in macular edema secondary to inflammation, a patient population with severe disease and no approved intravitreal biologic therapy. The breadth of this portfolio creates multiple opportunities to bring new medicines to patients across major retinal diseases.”

Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies. These milestones will bring us closer to our goal of improving vision for patients by providing retina specialists with new treatment options for both retinal vascular and inflammatory diseases.”